Studies related to HbA1c and Benfotiamine

The Effects Of Long-term Oral Benfotiamine Supplementation On Peripheral Nerve Function And Inflammatory Markers In Patients With Type 1 Diabetes: A 24-month, Double-blind, Randomized, Placebo-controlled Trial

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 67
Gender Both Genders
Notes for this study:
300mg of Benfotiamine daily for a period of 2 years in type 1 diabetics failed to improve nerve or glucose parameters relative to placebo.

A Double-blind, Randomized, Placebo-controlled Clinical Trial On Benfotiamine Treatment In Patients With Diabetic Nephropathy

Effect None
Trial Design Double blind
Trial Length n/a
Number of Subjects 63
Gender Both Genders
Age Range 45-64, 65+
Body Types Obese
Notes for this study:
In diabetic persons with 10-12 years of diabetes who failed to respond to ACE inhibitors or ARB therapy who were given 900mg benfotiamine (3x300mg) for 12 weeks failed to find any significant benefit of supplementation.